Novavax Inc. is starting 2019 on a high note, reporting positive phase 2 results for its flu vaccine candidate Thursday in what is expected to be a critical year for the Gaithersburg biotech.
The clinical trial for NanoFlu, which compared elderly adults’ immune responses to two flu vaccines on the market, found that its formulations were well-tolerated — and 50 percent more effective than market leader Fluzone High-Dose.
The results sent Novavax (NASDAQ: NVAX) shares up more than 6 percent…
